Safety and treatment volumes achieved following new developments of the magnetic resonance-guided focused ultrasound system in the treatment of uterine fibroids: a cohort study

Journal of Therapeutic Ultrasound

Wladyslaw M Gedroyc²  Lesley Regan¹  John Vedelago²  Stephen Derek Quinn¹ 

[1] Department of Obstetrics and Gynecology, St. Mary's Hospital, Imperial College London, South Wharf Road, London, UK;Deparment of Radiology, St. Mary's Hospital, Imperial College London, Praed Street, London, UK

关键词: Leiomyoma;    Magnetic resonance-guided focused ultrasound;    Uterine fibroids;   

Others  :  801368
DOI  :  10.1186/2050-5736-1-20

 received in 2013-02-22, accepted in 2013-07-15,  发布年份 2013

【 摘 要 】

Background

This research investigates whether modifications to the magnetic resonance-guided focused ultrasound ablation of uterine fibroid (MRgFUS) system used resulted in improved treatment volumes of uterine fibroids, while maintaining safety.

Methods

This study is a prospective cohort analysis of 34 women undergoing the ExAblate 2100 MRgFUS treatment for their uterine fibroids.

Results

The percentage of non-perfused volume (NPV) achieved with the ExAblate 2100 system was 54.92% compared with 50.49 % with the ExAblate 2000 system over the preceding year (p = 0.543). The ExAblate 2100 system resulted in a greater NPV in hyper-intense fibroids compared with the ExAblate 200 system (43.20% versus 36.33%, p = 0.005). There have been no recorded hospital admissions, no skins burns, and no reported major adverse events since the introduction of this new system.

Conclusion

Overall, the new system has thus far shown an encouraging safety record and an improvement in non-perfused volumes achieved, especially in hyper-intense fibroids.

【 授权许可】

   
2013 Quinn et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Stewart EA, Rabinovici J, Tempany CM, Inbar Y, Regan L, Gostout B, Hesley G, Kim HS, Hengst S, Gedroyc WM: Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006, 85(1):22-9.
• [2]Machtinger R, Inbar Y, Cohen-Eylon S, Admon D, Alagem-Mizrachi A, Rabinovici J: MR-guided focus ultrasound (MRgFUS) for symptomatic uterine fibroids: predictors of treatment success. Hum Reprod 2012, 27(12):3425-31.
• [3]Yoon SW, Seong SJ, Jung SG, Lee SY, Jun HS, Lee JT: Mitigation of abdominal scars during MR-guided focused ultrasound treatment of uterine leiomyomas with the use of an energy-blocking scar patch. J Vasc Interv Radiol 2011, 22(12):1747-50.
• [4]Okada A, Morita Y, Fukunishi H, Takeichi K, Murakami T: Non-invasive magnetic resonance-guided focused ultrasound treatment of uterine fibroids in a large Japanese population: impact of the learning curve on patient outcome. Ultrasound Obstet Gynecol 2009, 34(5):579-83.
• [5]Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1(8476):307-10.
• [6]Taran FA, Hesley GK, Gorny KR, Stewart EA: What factors currently limit magnetic resonance-guided focused ultrasound of leiomyomas? A survey conducted at the first international symposium devoted to clinical magnetic resonance-guided focused ultrasound. Fertil Steril 2010, 94(1):331-4.
• [7]Khaund A, Lumsden MA: Impact of fibroids on reproductive function. Best Pract Res Clin Obstet Gynaecol 2008, 22(4):749-60.